COG1-CDG

COG1-CDG (also known as Congenital Disorder of Glycosylation type IIg) is an extremely rare autosomal recessive metabolic disorder caused by mutations in the COG1 gene, which encodes a subunit of the Conserved Oligomeric Golgi (COG) complex. The COG complex plays a critical role in the proper functioning of the Golgi apparatus, which is essential for the glycosylation of proteins and lipids. Defects in COG1 lead to abnormal protein glycosylation, affecting multiple organ systems throughout the body. Clinical features of COG1-CDG typically present in infancy and include psychomotor retardation, failure to thrive, microcephaly, and generalized hypotonia. Affected individuals may also exhibit hepatosplenomegaly, mild to moderate liver dysfunction, skeletal abnormalities, and characteristic craniofacial dysmorphic features. Neurological involvement is prominent, with developmental delay, intellectual disability, and in some cases seizures. Growth retardation and feeding difficulties are commonly observed. Some patients may also present with cardiac abnormalities and recurrent infections due to immune dysfunction. Diagnosis is typically established through isoelectric focusing of serum transferrin, which reveals an abnormal type 2 pattern indicative of a Golgi glycosylation defect, and is confirmed by molecular genetic testing of the COG1 gene. There is currently no specific curative treatment for COG1-CDG. Management is supportive and symptomatic, involving a multidisciplinary team including neurologists, gastroenterologists, and developmental specialists. Physical therapy, occupational therapy, and nutritional support are important components of care. The long-term prognosis varies depending on the severity of organ involvement.

Common questions about COG1-CDG